1093 related articles for article (PubMed ID: 25147012)
1. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
4. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism.
Kang N; Sobieraj DM
Thromb Res; 2014 Jun; 133(6):1145-51. PubMed ID: 24713109
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV
J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
8. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
9. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
11. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
15. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Loffredo L; Violi F; Perri L
Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
[TBL] [Abstract][Full Text] [Related]
17. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ; Ziebell CM
Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
[TBL] [Abstract][Full Text] [Related]
18. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
